1. THRIVE Research Grant Program, International Life Sciences Institute (ILSI)/Health and Environmental Sciences Institute (HESI)

The THRIVE grant program is designed to provide seed funding to investigators for the testing of initial hypotheses and collecting of preliminary data to help secure long-term funding by the National Institutes of Health and/or other major granting institutions. The proposed study's scientific merit, innovation, and ability to translate from preclinical to clinical research (or vice versa) is key to being selected for funding. Preference will be given to studies in which both a non-clinical and clinical researcher are engaged in either design, conduct, or analysis of the study results.

The THRIVE program seeks to chart new futures for cancer survivors by Making Patient Quality of Life an Active Research Priority. This program fills a critical gap in funding for foundational research in support of future protective therapies, mitigation strategies and a next generation of drugs that will enhance the ability for cancer survivors to THRIVE.

THRIVE offers funding for basic science, clinical, and translational research that enhances our ability to predict when and how adverse effects may occur in patients who have received cancer treatment and supports the development of approaches to avoid or lessen these effects. By providing researchers with both seed funding and access to critical networks, THRIVE will enhance the visibility of the patient need, the value of the research, and the reasons that larger funding entities might elect to incorporate these research streams into future funding priorities.

This unique program focuses on innovative cross-disciplinary research with defined impact for patients. THRIVE gives preference to those innovative research projects that engage both non-clinical AND clinical scientists in the research project design and/or implementation. We believe that research at the translational boundary can make significant impact on the science and patients. This research will advance our:

- Fundamental understanding of cancer drug or therapy-related toxicity;
- Ability to identify and translate critical biomarkers of toxicity;
- Models (in vivo, in vitro, in silico) of pediatric or adult drug exposure that predict early or impending toxicities; and/or

---

Do you want to learn more about identifying external funding opportunities? See ECOR's website for information on the funding opps database, COS Pivot or contact Amy Robb arobb@mgh.harvard.edu for a research consultation.
• Understanding of the role of protective co-therapies or modified exposure protocols on the onset of therapy-induced damage.
• Identification of novel protective therapies or dosing-strategies

Award Amount: Up to $50,000 for 2 years
LOI Deadline: Jul 15, 2016
Website: http://hesithrive.org/grant-guidelines/

2. Brian D. Novis Junior Research Award, International Myeloma Foundation (IMF)
These awards go to researchers doing work in the field of multiple myeloma and related disorders including smoldering myeloma, MGUS (monoclonal gammopathy of undetermined significance) as well as immunoglobulin derived amyloidosis. The Award Committee will consider most favorably those proposals that provide evidence of an applicant’s research initiative and creativity. The Committee will also weigh the previous accomplishments of the applicant, the probability of meaningful results from the proposed research, and the likely contribution of the research to the advancement of our knowledge of myeloma etiology, diagnosis, treatment, or prevention.

Award Amount: $50,000 for 1 year
Application Deadline: Aug 1, 2016
Website: http://myeloma.org/ArticlePage.action?tabId=12&menuId=370&articleId=69&aTab=1

3. Innovative Grant Program, JDRF
JDRF is focused on funding and catalyzing research that will lead to a cure of Type 1 diabetes (T1D) (previously known as juvenile diabetes), improving the quality of life and relieving the burden for people living with T1D, and preventing the disease. JDRF provides seed funding for highly innovative research with significant potential to accelerate the mission of JDRF. Proposals should address key outstanding questions and have the potential to lead to a change in the current paradigm or conventional wisdom and/or lead to a groundbreaking discovery. Preliminary data is not required in the proposal but the underlying premise, goal, or hypothesis must be plausible and testable and the proposal must be focused with a well-defined goal that is achievable within the timeframe of the award. The Innovative Grant is not intended to support proposals aiming to incrementally advance existing hypotheses, ongoing areas of research or proposals with the sole goal of generating novel reagents or resources.

Award Amount: $110,000 for 1 year
Application Deadline: Jul 30, 2016
Website: http://grantcenter.jdrf.org/grant-center/information-for-applicants/grant-mechanism-descriptions/innovative-grants/
4. Career Catalyst Research (CCR) Grants -- Basic and Translational Research, Susan G. Komen for the Cure

CCR Grants are intended to foster promising breast cancer researchers who are in the early stages of their faculty careers by providing support for up to three years of "protected time" for research career development under the guidance of a Mentor Committee. It is expected that awardees will launch independent research careers and successfully compete for subsequent research project funding in breast cancer following the successful completion of a CCR Grant, thereby playing key roles in reducing breast cancer incidence and mortality, with the ultimate goal of ending breast cancer forever.

The Letter of Intent must propose hypothesis-driven research that directly relates to breast cancer and clearly describes the significant potential to lead to reductions in breast cancer incidence and/or mortality within the next decade. Research that does not directly relate to breast cancer will be administratively withdrawn from consideration and will not be reviewed or scored.

Basic/Translational: CCR - Basic/Translational Research Grants provide support for hypothesis-driven research projects that are laboratory- or field-based and do not meet Komen’s definition of clinical research. Studies focusing on quality of life or survivorship issues are not appropriate for this research focus area. A project involving clinical trial samples for a study in conjunction with a clinician that does not involve the Applicant having direct patient interaction would also be appropriate for the Basic/Translational Focus area.

Letters of Intent that relate to mitigating post-treatment effects (i.e., Quality of Life applications) could be seen as contributing to the reduction of mortality, such as those projects focused on cardiotoxicity, etc. In addition, some applications may deal with encouraging segments of the population to be screened, and thus overcome barriers to early detection—again, this is seen as directly related to Komen’s mission to reduce mortality.

Grants will be awarded to a single Principal Investigator (PI). Co-Principal Investigators (Co-PIs) are not allowed.

The Susan G. Komen Tissue Bank at the Indiana University Simon Cancer Center (KTB) is the only repository in the world for normal breast tissue and matched serum, plasma and DNA. It is a goal of the KTB to acquire biomolecules and tissue specimens from the entire continuum of breast development from puberty to menopause. The KTB collects the following types of samples: fresh frozen tissue; formalin-fixed paraffin-embedded (FFPE) tissue; blood products including whole blood, plasma, serum; and DNA from lymphocytes. These samples are available to investigators to conduct research which will provide insight into breast oncogenesis. Additionally, the KTB has created a virtual tissue bank which will be populated with data derived from research completed with KTB samples; other researchers from around the world will be able to access this data.
The KTB invites researchers to take advantage of the available normal breast tissue to understand the biology of breast cancer. Komen is encouraging the use of this unique resource by inviting Applicants/PIs to include plans for utilizing tissues from the KTB in their grant applications.

Award Amount: $450,000 paid over 3 years
LOI Deadline: Jul 14, 2016
Website:  http://ww5.komen.org/ResearchGrants/FundingOpportunities.html

5. Career Catalyst Research (CCR) Grants -- Clinical Research, Susan G. Komen for the Cure

CCR Grants are intended to foster promising breast cancer researchers who are in the early stages of their faculty careers by providing support for up to three years of "protected time" for research career development under the guidance of a Mentor Committee. It is expected that awardees will launch independent research careers and successfully compete for subsequent research project funding in breast cancer following the successful completion of a CCR Grant, thereby playing key roles in reducing breast cancer incidence and mortality, with the ultimate goal of ending breast cancer forever.

The Letter of Intent must propose hypothesis-driven research that directly relates to breast cancer and clearly describes the significant potential to lead to reductions in breast cancer incidence and/or mortality within the next decade. Research that does not directly relate to breast cancer will be administratively withdrawn from consideration and will not be reviewed or scored.

Clinical: CCR - Clinical Research Grants provide support for either MD or PhD Applicants for hypothesis-driven, patient-oriented research for which an investigator directly interacts with human subjects/patients. Such studies may be conducted in conjunction with laboratory-based research, as appropriate. This includes studies such as therapeutic interventions or clinical trials. *Clinical trials are research studies that involve people and explore whether a medical strategy, treatment, or device is safe and effective for humans. A clinical trial may also be observational, where individuals are only observed and the outcomes measured by researchers.

Letters of Intent that relate to mitigating post-treatment effects (i.e., Quality of Life applications) could be seen as contributing to the reduction of mortality, such as those projects focused on cardiotoxicity, etc. In addition, some applications may deal with encouraging segments of the population to be screened, and thus overcome barriers to early detection—again, this is seen as directly related to Komen's mission to reduce mortality.

Grants will be awarded to a single Principal Investigator (PI). Co-Principal Investigators (Co-PIs) are not allowed.
The Susan G. Komen Tissue Bank at the Indiana University Simon Cancer Center (KTB) is the only repository in the world for normal breast tissue and matched serum, plasma and DNA. It is a goal of the KTB to acquire biomolecules and tissue specimens from the entire continuum of breast development from puberty to menopause. The KTB collects the following types of samples: fresh frozen tissue; formalin-fixed paraffin-embedded (FFPE) tissue; blood products including whole blood, plasma, serum; and DNA from lymphocytes. These samples are available to investigators to conduct research which will provide insight into breast oncogenesis. Additionally, the KTB has created a virtual tissue bank which will be populated with data derived from research completed with KTB samples; other researchers from around the world will be able to access this data.

The KTB invites researchers to take advantage of the available normal breast tissue to understand the biology of breast cancer. Komen is encouraging the use of this unique resource by inviting Applicants/PIs to include plans for utilizing tissues from the KTB in their grant applications.

Award Amount: $450,000 for up to 3 years
LOI Deadline: Jul 14, 2016
Website: [http://ww5.komen.org/ResearchGrants/FundingOpportunities.html](http://ww5.komen.org/ResearchGrants/FundingOpportunities.html)

6. Postdoctoral Fellowship (PDF) Grants – Basic/Translational and Clinical Research, Susan G. Komen for the Cure

Postdoctoral Fellowship (PDF) Grants are intended to attract and support promising scientists and clinician/scientists who are embarking on careers dedicated to breast cancer research. By providing funding to outstanding postdoctoral/postgraduate fellows under the guidance of a mentor, Komen seeks to ensure that a diverse pool of highly trained scientists will emerge as the next generation of leaders in the field of breast cancer research. These leaders will play key roles in reducing breast cancer incidence and mortality within in the next decade, with the ultimate goal of ending breast cancer forever.

The Letter of Intent must propose research that directly relates to breast cancer and clearly describes the significant potential to lead to reductions in breast cancer incidence and/or mortality within the next decade, or otherwise will be administratively withdrawn from consideration and will not be reviewed or scored.

1. Basic/Translational

PDF-Basic/Translational Research Grants provide support for hypothesis-driven research projects that are laboratory-or field-based and do not meet Komen’s definition of clinical research. Studies focusing on quality of life or survivorship issues are not appropriate for this research focus area. A project involving clinical trial samples for a study in conjunction with a clinician that does not involve the Applicant having direct patient interaction would also be appropriate for the Basic/Translational Focus area.
2. Clinical
PDF-Clinical Research Grants provide support for either MD or PhD. Applicants for hypothesis driven, patient-oriented research for which an investigator directly interacts with human subjects/patients. Such studies may be conducted in conjunction with laboratory-based research, as appropriate. This includes studies such as therapeutic interventions or clinical trials. *Clinical trials are research studies that involve people and explore whether a medical strategy, treatment, or device is safe and effective for humans. A clinical trial may also be observational, where individuals are only observed and the outcomes measured by researchers.

*Note: Clinical trials require that all subjects provide informed consent. If a project is not consenting patients, but rather using patient samples collected previously, then it is not considered a clinical trial. Letters of Intent that relate to mitigating post-treatment effects (i.e., Quality of Life applications) could be seen as contributing to the reduction of mortality, such as those projects focused on cardiotoxicity, etc. In addition, some applications may deal with encouraging segments of the population to be screened, and thus overcome barriers to early detection – again, this is seen as directly related to Komen’s mission to reduce mortality.

Award Amount: Up to $180,000 for 2 years
LOI Deadline: Jul 14, 2016
Website: [http://ww5.komen.org/ResearchGrants/FundingOpportunities.html](http://ww5.komen.org/ResearchGrants/FundingOpportunities.html)

7. NAF Pioneer SCA Translational Research Awards, National Ataxia Foundation (NAF)
NAF invites proposals, under a competitive Request for Applications (RFA) process, to award a grant focusing on research investigations that will facilitate the development of treatments for the Spinocerebellar Ataxias (SCAs).

Award Amount: $100,000 for 1 year
LOI Deadline: Aug 15, 2016
Website: [http://www.ataxia.org/research/ataxia-research-grants.aspx](http://www.ataxia.org/research/ataxia-research-grants.aspx)